On Jul. 25, 2024, the California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, awarded nearly $35 million to fund clinical research to address a rare plasma cell disorder and six new Shared Resources Laboratories (SLR), an important component of CIRM’s infrastructure program.

The award was made through the Agency’s clinical program, which provided funding for eligible stem cell and gene therapy-based projects through all stages of clinical trial development. This award brought the number of CIRM-funded clinical trials to 109.